Clinical Neuropharmacology · 2002 · 120 citations · 29 references
MedicinePharmacologyPsychiatryNeuropsychiatryNeuropsychologyPsychopharmacologyChild PsychopharmacologyNeurodevelopmental DisordersNeuropsychiatric DisordersPediatric NeuropsychiatryPsychopharmacology In ChildrenTourette SyndromeAlpha-adrenergic AgonistsNeurocognitive FunctioningNeuropsychiatric EffectsNeuropsychological FunctioningPediatric Tourette Syndrome TreatmentPharmacotherapy For TicsPlacebo-controlled Efficacy AssessmentTic Severity Assessment
The objective of this study was to evaluate the neuropsychiatric effects of the alpha-2a adrenergic agonist guanfacine in children with Tourette syndrome (TS). Twenty-four children with TS participated in a 4-week, double-blind, placebo-controlled study of guanfacine. Tic severity, neuropsychologic functioning, and parent ratings of behavior were evaluated pre- and post-treatment. The sample had mild tic severity and subtle neuropsychologic dysfunction pretreatment. Post-treatment, patients receiving guanfacine were rated by parents as significantly improved (compared to placebo) on one measure of executive function (parent-rated metacognition). Improvement on tic severity, performance-based neuropsychologic measures, and all other parent ratings were not significantly better than placebo. At a moderate dose and short-term treatment duration, guanfacine did not provide significant neuropsychiatric benefits in this group of children with mild TS.
29
Improving the Quality of Reporting of Randomized Controlled Trials
Colin B. Begg · JAMA · 1996 · 3.1K citations